AC   CVCL_0525
SY   SK-Hep-1; SK HEP-1; SK HEP 01; SK-Hep1; Sk-Hep1; SK Hep1; SKHEP-1; SKHEP1; SKHep1; SK_HEP1
DR   BTO; BTO:0003477
DR   CLO; CLO_0009037
DR   MCCL; MCC:0000425
DR   CLDB; cl4312
DR   CLDB; cl4313
DR   CLDB; cl4314
DR   CLDB; cl4315
DR   CLDB; cl7214
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 467
DR   BioSample; SAMN01821598
DR   BioSample; SAMN01821664
DR   BioSample; SAMN03472884
DR   BioSample; SAMN10988022
DR   cancercelllines; CVCL_0525
DR   CCRID; 1101HUM-PUMC000677
DR   CCRID; 1102HUM-NIFDC00060
DR   CCRID; 3101HUMTCHu109
DR   CCRID; 4201HUM-CCTCC00145
DR   Cell_Model_Passport; SIDM01110
DR   CGH-DB; 9071-4
DR   ChEMBL-Cells; CHEMBL3307741
DR   ChEMBL-Targets; CHEMBL614912
DR   CLS; 300334
DR   Cosmic; 684195
DR   Cosmic; 928139
DR   Cosmic; 932990
DR   Cosmic; 979728
DR   Cosmic; 873394
DR   Cosmic; 735607
DR   Cosmic; 909719
DR   Cosmic; 1187333
DR   Cosmic; 1518231
DR   Cosmic; 2162539
DR   Cosmic; 2321042
DR   Cosmic; 2668284
DR   Cosmic-CLP; 909719
DR   DepMap; ACH-000361
DR   DSMZ; ACC-141
DR   DSMZCellDive; ACC-141
DR   ECACC; 91091816
DR   EGA; EGAS00001000978
DR   FCS-free; 174-2-331-1-4-3
DR   GDSC; 909719
DR   GEO; GSM481451
DR   GEO; GSM501784
DR   GEO; GSM565878
DR   GEO; GSM887578
DR   GEO; GSM888661
DR   GEO; GSM936776
DR   GEO; GSM1374879
DR   GEO; GSM1670432
DR   GEO; GSM2551582
DR   IARC_TP53; 27577
DR   ICLC; HTL10001
DR   KCB; KCB 2013038YJ
DR   KCLB; 30052
DR   LiGeA; CCLE_110
DR   PharmacoDB; SKHEP1_1390_2019
DR   PRIDE; PXD002957
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0525
DR   PubChem_Cell_line; CVCL_0525
DR   TOKU-E; 3132
DR   Ubigene; YC-C007
DR   Wikidata; Q54953666
RX   DOI=10.1007/978-1-4757-1647-4_5;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=924690;
RX   PubMed=1371504;
RX   PubMed=2439335;
RX   PubMed=3518877;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=7017212;
RX   PubMed=7459858;
RX   PubMed=8224613;
RX   PubMed=8389256;
RX   PubMed=9023415;
RX   PubMed=9178645;
RX   PubMed=11416159;
RX   PubMed=12029633;
RX   PubMed=12068308;
RX   PubMed=20069059;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23505090;
RX   PubMed=23887712;
RX   PubMed=25574106;
RX   PubMed=25822314;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31938418;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Problematic cell line: Misclassified. Originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells (PubMed=1371504; PubMed=31938418).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-535.
CC   Population: Caucasian.
CC   Doubling time: 46.7 +- 10.3 hours, 94.2 hours (Note=In CDM4-CHO medium), 289.8 hours (Note=In 293 SFM II medium) (PubMed=25822314); ~30 hours (DSMZ=ACC-141).
CC   HLA typing: A*02:01,24:02; B*35:04,44:03:01; C*04:01; DQA1*01:02; DQB1*05:02,06.04; DRB1*13:02,16:02 (PubMed=9178645).
CC   HLA typing: A*02:01,24:02; B*35:02,44:03; C*04:01,04:01 (PubMed=26589293).
CC   Karyotypic information: Has lost chromosome Y.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.65%; Native American=1.18%; East Asian, North=0%; East Asian, South=2.22%; South Asian=8.09%; European, North=23.66%; European, South=64.2% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
CC   Cell type: Endothelial cell; CL=CL_0000115.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; MSKCC; PubMed=11416159; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D12S391: 18
ST   D13S317: 8,12
ST   D16S539: 12
ST   D18S51: 13,15
ST   D19S433: 12 (DSMZ)
ST   D19S433: 12,15.2 (CCRID; CLS; MSKCC; PubMed=25877200)
ST   D21S11: 29,31
ST   D2S1338: 20,23
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D6S1043: 11
ST   D7S820: 8,11
ST   D8S1179: 13,14
ST   FGA: 17
ST   Penta D: 13,14
ST   Penta E: 13 (PubMed=25877200)
ST   Penta E: 13,21 (CCRID; CLS; DSMZ)
ST   TH01: 7,9
ST   TPOX: 9
ST   vWA: 14,17
DI   NCIt; C7106; Liver and intrahepatic bile duct epithelial neoplasm
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
RX   DOI=10.1007/978-1-4757-1647-4_5;
RA   Fogh J., Trempe G.L.;
RT   "New human tumor cell lines.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975).
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=924690; DOI=10.1002/ijc.2910200505;
RA   Kerbel R.S., Pross H.F., Leibovitz A.;
RT   "Analysis of established human carcinoma cell lines for
RT   lymphoreticular-associated membrane receptors.";
RL   Int. J. Cancer 20:673-679(1977).
RX   PubMed=1371504; DOI=10.1007/BF02631017;
RA   Heffelfinger S.C., Hawkins H.H., Barrish J., Taylor L.,
RA   Darlington G.J.;
RT   "SK HEP-1: a human cell line of endothelial origin.";
RL   In Vitro Cell. Dev. Biol. Anim. 28:136-142(1992).
RX   PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x;
RA   Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J.,
RA   Revillard J.-P.;
RT   "Purification of alpha 1-microglobulin produced by human hepatoma cell
RT   lines. Biochemical characterization and comparison with alpha
RT   1-microglobulin synthesized by human hepatocytes.";
RL   Eur. J. Biochem. 165:699-704(1987).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613;
RA   Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E.,
RA   Ponchel F., Yakicier C., Ji J.-W., Ozturk M.;
RT   "Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell
RT   lines.";
RL   FASEB J. 7:1407-1413(1993).
RX   PubMed=8389256; DOI=10.1093/carcin/14.5.987;
RA   Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T.,
RA   Harris C.C.;
RT   "p53 gene mutation and integrated hepatitis B viral DNA sequences in
RT   human liver cancer cell lines.";
RL   Carcinogenesis 14:987-992(1993).
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=20069059; DOI=10.1155/2010/437143;
RA   Srisomsap C., Sawangareetrakul P., Subhasitanont P.,
RA   Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S.,
RA   Svasti J.;
RT   "Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma
RT   cell secretomes.";
RL   J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z.,
RA   Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K.,
RA   Xu J.-C.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
RX   PubMed=25574106; DOI=10.3748/wjg.v21.i1.311;
RA   Cevik D., Yildiz G., Ozturk M.;
RT   "Common telomerase reverse transcriptase promoter mutations in
RT   hepatocellular carcinomas from different geographical locations.";
RL   World J. Gastroenterol. 21:311-317(2015).
RX   PubMed=25822314; DOI=10.1007/s00449-015-1392-9;
RA   Biaggio R.T., de Abreu-Neto M.S., Covas D.T., Swiech K.;
RT   "Serum-free suspension culturing of human cells: adaptation, growth,
RT   and cryopreservation.";
RL   Bioprocess Biosyst. Eng. 38:1495-1507(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31938418;
RA   Tai Y., Gao J.-H., Zhao C., Tong H., Zheng S.-P., Huang Z.-Y., Liu R.,
RA   Tang C.-W., Li J.;
RT   "SK-Hep1: not hepatocellular carcinoma cells but a cell model for
RT   liver sinusoidal endothelial cells.";
RL   Int. J. Clin. Exp. Pathol. 11:2931-2938(2018).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).